We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

COVID-19 mRNA Vaccines Safe in Patients With Heart Failure

Credit: Spencer Davis/ Pixabay

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "COVID-19 mRNA Vaccines Safe in Patients With Heart Failure"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

COVID mRNA vaccines are associated with a decreased risk of death in patients with heart failure, according to research presented at ESC Congress 2022.1 The study also found that the vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism or myocarditis in heart failure patients.


“Our results indicate that heart failure patients should be prioritised for COVID-19 vaccinations and boosters,” said study author Dr. Caroline Sindet-Pedersen of Herlev and Gentofe Hospital, Hellerup, Denmark. “COVID-19 vaccines will continue to be important for preventing morbidity and mortality in vulnerable patient populations. Thus, studies emphasising the safety of these vaccines are essential to reassure those who might be hesitant and ensure continued uptake of vaccinations.”


Patients with heart failure are at increased risk of hospitalisation, need for mechanical ventilation, and death due to COVID-19.2 Vaccination reduces the risk of serious illness from COVID-19. However, “Due to perceptions about possible cardiovascular side effects from mRNA vaccines in heart failure patients, this study examined the risk of cardiovascular complications and death associated with mRNA vaccines in a nationwide cohort of patients with heart failure,” said Dr. Sindet-Pedersen.


The study included 50,893 unvaccinated patients with heart failure in 2019 and 50,893 patients with heart failure in 2021 who were vaccinated with either of the two mRNA vaccines (BNT162B2 or mRNA-1273).3 The two groups were matched for age, sex, and duration of heart failure. The median age of participants was 74 years and 35% were women. The median duration of heart failure was 4.1 years. Participants were followed for 90 days for all-cause mortality, worsening heart failure, venous thromboembolism, and myocarditis, starting from the date of the second vaccination for the 2021 group and the same date in 2019 for the unvaccinated group.


The researchers compared the risk of adverse outcomes in the two groups, after standardising for age, sex, heart failure duration, use of heart failure medications, ischaemic heart disease, cancer, diabetes, atrial fibrillation, and admission with heart failure less than 90 days before the first date of follow up. Dr. Sindet-Pedersen explained: “Standardisation imitates a randomised trial and is a way to obtain a better causal interpretation of the results from observational studies.”


Among 101,786 heart failure patients, the researchers found that receiving an mRNA vaccine was not associated with an increased risk of worsening heart failure, myocarditis or venous thromboembolism but was associated with a decreased risk of all-cause mortality. The standardised risk of all-cause mortality within 90 days was 2.2% in the 2021 cohort (vaccinated) and 2.6% in the 2019 cohort (not vaccinated), showing a significantly lower risk for all-cause mortality in 2021 versus 2019. The standardised risk of worsening heart failure within 90 days was 1.1% in both cohorts. Similarly, no significant differences were found between groups for venous thromboembolism or myocarditis.


Dr. Sindet-Pedersen concluded: “The study suggests that there should be no concern about cardiovascular side effects from mRNA vaccines in heart failure patients. In addition, the results point to a beneficial effect of vaccination on mortality.”


Reference: Sindet-Pedersen C. Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study. To be presented at the European Society of Cardiology Congress 2022. August 2022. Barcelona, Spain. https://www.escardio.org/The-ESC/Press-Office/Press-releases/COVID-mRNA-vaccines-are-safe-in-patients-with-heart-failure. Accessed August 22, 2022.


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

  
Advertisement